Axovant Sciences (NASDAQ:AXON)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a research report issued to clients and investors on Friday. They presently have a $11.00 target price on the biotechnology company’s stock. HC Wainwright’s price target would suggest a potential upside of 99.28% from the stock’s previous close.

AXON has been the topic of a number of other research reports. BidaskClub upgraded Axovant Sciences from a “strong sell” rating to a “sell” rating in a research report on Saturday, September 23rd. Chardan Capital reiterated a “sell” rating and set a $8.00 price objective on shares of Axovant Sciences in a research report on Thursday, September 14th. Piper Jaffray Companies reiterated a “hold” rating on shares of Axovant Sciences in a research report on Friday, November 10th. Evercore ISI initiated coverage on Axovant Sciences in a research report on Friday, September 8th. They set an “outperform” rating and a $30.00 price objective on the stock. Finally, Robert W. Baird reissued a “hold” rating and set a $6.00 target price on shares of Axovant Sciences in a research note on Wednesday, November 1st. Three investment analysts have rated the stock with a sell rating, six have assigned a hold rating and six have assigned a buy rating to the company. The stock presently has an average rating of “Hold” and an average target price of $14.13.

Shares of Axovant Sciences (AXON) traded up $0.22 during trading on Friday, reaching $5.52. The company had a trading volume of 544,300 shares, compared to its average volume of 1,019,414. Axovant Sciences has a 52-week low of $4.60 and a 52-week high of $27.98. The company has a current ratio of 5.94, a quick ratio of 5.94 and a debt-to-equity ratio of 0.34.

Several hedge funds and other institutional investors have recently modified their holdings of AXON. Oppenheimer & Co. Inc. acquired a new stake in shares of Axovant Sciences in the third quarter valued at $101,000. Bank of America Corp DE grew its stake in shares of Axovant Sciences by 38.9% in the first quarter. Bank of America Corp DE now owns 7,396 shares of the biotechnology company’s stock valued at $111,000 after buying an additional 2,072 shares in the last quarter. Cubist Systematic Strategies LLC acquired a new stake in shares of Axovant Sciences in the third quarter valued at $117,000. Legal & General Group Plc grew its stake in shares of Axovant Sciences by 20.2% in the second quarter. Legal & General Group Plc now owns 6,955 shares of the biotechnology company’s stock valued at $162,000 after buying an additional 1,168 shares in the last quarter. Finally, Russell Investments Group Ltd. grew its stake in shares of Axovant Sciences by 38.5% in the second quarter. Russell Investments Group Ltd. now owns 10,041 shares of the biotechnology company’s stock valued at $233,000 after buying an additional 2,789 shares in the last quarter. 96.93% of the stock is owned by institutional investors and hedge funds.

WARNING: This piece was originally posted by American Banking News and is owned by of American Banking News. If you are accessing this piece on another site, it was stolen and republished in violation of international copyright & trademark laws. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2017/12/01/axovant-sciences-axon-buy-rating-reiterated-at-hc-wainwright.html.

About Axovant Sciences

Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer’s disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.

Analyst Recommendations for Axovant Sciences (NASDAQ:AXON)

Receive News & Ratings for Axovant Sciences Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.